Organisation paid for research Program year 2024 Source: CMS Open Payments

Dana Farber Partners Cancercare, Inc.

Neither a doctor nor a teaching hospital

Research payments

$2,181,819

108 payments

Through program year 2024, Dana Farber Partners Cancercare, Inc. is reported as receiving $2,181,819 in research payments, across 108 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $31,183 2
2023 Research $16,712 3
2020 Research $299,358 17
2019 Research $1,834,565 86

Breakdown

Who paid Research payments · program years 2019–2024
  1. Daiichi Sankyo Inc. $1,328,866 58 payments
  2. Exelixis Inc. $745,147 36 payments
  3. Rigel Pharmaceuticals, Inc. $59,910 9 payments
  4. Corcept Therapeutics $47,895 5 payments
Studies the money was for Research payments · program years 2019–2024
  1. Study name not reported $748,675 25 payments
  2. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $567,949 22 payments
  3. Study name not reported $455,302 22 payments
  4. A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris $126,872 11 payments
  5. Study name not reported $105,239 10 payments
  6. C-935788-053 $59,910 9 payments
  7. A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors $50,326 3 payments
  8. Cort125134-552 $47,895 5 payments
  9. Study name not reported $19,650 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record